Meisoindigo TAC CRABP-II Degrader-1 a novel and potent p21-activated

a novel and potent p21-activated kinase 4 inhibitor

CK-1827452 improves systolic function by increasing the systolic ejection duration/stroke volume

is discovered to inhibit JNK kinase by broad-base kinase selectivity profiling of a library of acrylamide kinase inhibitors based on the structure of imatinib using the KinomeSca approach

volumes of 3

EED inhibitor1

Meisoindigo TAC CRABP-II Degrader-1 a novel and potent p21-activatedMeisoindigo, also known as N Methylisoindigotin and Dian III, is an apoptosis inducer and potential agent for AML. Meisoindigo has been a routine therapeutic agent in the clinical treatment of chronic myelogenous leukemia (CML) in China since the 1980s. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Product information CAS Number: 97207 47 1 Molecular Weight: 276. 29 Formula: C17H12N2O2